TAKEDA PHARMACEUTICALS AMERICA, INC. for TAKEDA PHARMACEUTICALS AMERICA INC
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 20, 2011 | $455,000 | Replaced |
| 1st Quarter - Amendment (this page) | Jul 20, 2011 | $445,000 | Yes |
What was lobbied
9 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
S. 3036 National Alzheimers Project Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA WILKINSON | — |
Budget/Appropriations BUD
5th Continuing Resolution HJRes44; 6th Continuing Resolution HJRes48; Department of Defense and Further Additional Continuing Appropriations Act, 2011 H1363; Department of Defense and Full-Year Continuing Appropriations Act, 2011 H1473;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA WILKINSON | — |
Law Enforcement/Crime/Criminal Justice LAW
HR 816 Provider Shield Act of 2011 Medical malpractice reforms
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA WILKINSON | — |
Taxation/Internal Revenue Code TAX
Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt and deficit commission recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act section 9006, referred to as 1099 provision; Innovate America Act; Ryan Roadmap;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA WILKINSON | — |
Trade (domestic/foreign) TRD
Importation issues, Preserve Access to Affordable Generics Act; S. 319 Pharmaceutical Market Access and Drug Safety Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA WILKINSON | — |
Manufacturing MAN
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA WILKINSON | — |
Copyright/Patent/Trademark CPT
S. 23 Patent Reform Act of 2011; S. 27 Preserve Access to Affordable Generics
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA WILKINSON | — |
Health Issues HCR
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURA ELIZABETH CLINE | — |
| DEBORAH LYNN WALTER | — |
| ANDREA WILKINSON | — |
Medicare/Medicaid MMM
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap ;
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURA ELIZABETH CLINE | — |
| DEBORAH LYNN WALTER | — |
| ANDREA WILKINSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.